TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection 908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
Speaking at a Canaccord Genuity event, President, CEO and Co-Founder K
TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript BRIUMVI revenue surged 64% year-over-year as patient starts hit record levels.
TG Therapeutics Q2 Earnings Call Highlights TG Therapeutics (
NASDAQ:TGTX ) reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment per
2 Fast-Growing Pharmaceutical Stocks to Buy Now Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.
TG Therapeutics Stock Surges After Drug Trial Update Shares of TG Therapeutics Inc (
NASDAQ: TGTX ) are climbing Wednesday after early-stage clinical trial data for new BRIUMVI MS formulation.
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States.
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position This clinical-stage biotech develops oral therapeutics for chronic diseases, targeting large global markets with unmet medical needs.
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.
Soleus Adds a Significant Number of Celcuity Shares This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win' TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.
